GlassScriptPhysician profile
Shari Rosenbaum
NPI 1750307823
$4,467.71
in general payments reported to CMS, 2019-2025
23 companies · $501 in 2025
The $501 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,154 · 2020: $2,412 · 2021: $14.52 · 2022: $121 · 2023: $24.08 · 2024: $240 · 2025: $501.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $766.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $765.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aesculap Implant Systems, LLC | $1,970.00 | 2020 | |
| Lilly USA, LLC | $294.92 | 2019-2025 | Zepbound, Mounjaro |
| Amgen INC. | $236.92 | 2019-2025 | Repatha, Otezla |
| Amarin Pharma, INC. | $191.39 | 2019-2020 | |
| Pfizer INC. | $173.57 | 2019-2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $167.77 | 2019-2020 | |
| Novo Nordisk INC | $160.58 | 2019-2025 | Wegovy |
| Astellas Pharma US INC | $158.62 | 2019-2020 | |
| Sonex Health, INC. | $157.67 | 2025 | Sx-One Microknife |
| Kowa Pharmaceuticals America, INC. | $111.13 | 2019-2024 | Livalo |
| Novartis Pharmaceuticals Corporation | $103.01 | 2022-2025 | |
| Abbvie INC. | $102.93 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $102.79 | 2019-2020 | |
| Glaxosmithkline, LLC. | $102.72 | 2019-2025 | Arexvy, Shingrix |
| Janssen Pharmaceuticals, INC | $100.19 | 2019-2020 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $90.24 | 2019-2020 | |
| Saluda Medical Americas, INC. | $72.91 | 2025 | Evoke |
| Boehringer Ingelheim Pharmaceuticals, INC. | $43.51 | 2019-2020 | |
| Medicure Pharma INC. | $38.38 | 2025 | Zypitamag |
| Genentech USA, INC. | $37.82 | 2019 | |
| Esperion Therapeutics, INC. | $20.93 | 2024 | Nexletol |
| Regeneron Healthcare Solutions, INC. | $15.19 | 2019 | |
| Neurelis, INC. | $14.52 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shari Rosenbaum listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.